Ultragenyx Pharmaceutical (RARE) Non-Current Deferred Tax Liability (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Non-Current Deferred Tax Liability data on file, last reported at $30.0 million in Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $30.0 million, changed 0.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.0 million (changed 0.19% YoY), and the FY2025 annual result was $30.0 million, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability steadied at $30.0 million in Q1 2026 per RARE's latest filing, from $30.0 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $33.3 million in Q1 2022 and troughed at $30.0 million in Q4 2024.
• A 5-year average of $31.0 million and a median of $30.1 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability changed 0.0% in 2022, then dropped 5.08% in 2023.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $31.7 million in 2022, then retreated by 5.08% to $30.1 million in 2023, then fell by 0.19% to $30.0 million in 2024, then changed by 0.0% to $30.0 million in 2025, then changed by 0.0% to $30.0 million in 2026.
• Business Quant data shows RARE's Non-Current Deferred Tax Liability at $30.0 million in Q1 2026, $30.0 million in Q4 2025, and $30.1 million in Q3 2025.